$7.83
0.081.03%
At close: -
$8.15
0.324.09%
After Hours: Apr 7, 8:01 AM EDT
Comments
Loading...
MiNK Therapeutics Analyst Ratings and Price Targets | NASDAQ:INKT | Benzinga
MiNK Therapeutics Inc has a consensus price target of $14 based on the ratings of 3 analysts. The high is $35 issued by HC Wainwright & Co. on March 18, 2025. The low is $3 issued by Evercore ISI Group on March 22, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Baird on March 18, 2025, February 25, 2025, and November 15, 2024, respectively. With an average price target of $24.67 between HC Wainwright & Co., HC Wainwright & Co., and Baird, there's an implied 202.66% upside for MiNK Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Baird
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for MiNK Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 329.45% | HC Wainwright & Co. | Emily Bodnar36% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | 329.45% | HC Wainwright & Co. | Emily Bodnar36% | $9 → $35 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | -50.92% | Baird | Jack Allen 36% | $80 → $40 | Maintains | Outperform | Get Alert |
| 11/15/2024 | Buy Now | 10.43% | HC Wainwright & Co. | Emily Bodnar36% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2024 | Buy Now | 10.43% | HC Wainwright & Co. | Emily Bodnar36% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 10.43% | HC Wainwright & Co. | Emily Bodnar36% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 10.43% | HC Wainwright & Co. | Emily Bodnar36% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2024 | Buy Now | 10.43% | HC Wainwright & Co. | Emily Bodnar36% | $100 → $90 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 22.7% | HC Wainwright & Co. | Emily Bodnar36% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 22.7% | HC Wainwright & Co. | Emily Bodnar36% | $70 → $100 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | -14.11% | HC Wainwright & Co. | Emily Bodnar36% | → $70 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | Buy Now | -63.19% | Evercore ISI Group | Maneka Mirchandaney25% | $40 → $30 | Maintains | Outperform | Get Alert |
| 03/22/2023 | Buy Now | -14.11% | HC Wainwright & Co. | Emily Bodnar36% | → $70 | Reiterates | → Buy | Get Alert |
| 08/10/2022 | Buy Now | -14.11% | HC Wainwright & Co. | Emily Bodnar36% | → $70 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for MiNK Therapeutics (INKT) stock?
The latest price target for MiNK Therapeutics (NASDAQ:INKT) was reported by HC Wainwright & Co. on March 18, 2025. The analyst firm set a price target for $35.00 expecting INKT to rise to within 12 months (a possible 329.45% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MiNK Therapeutics (INKT)?
The latest analyst rating for MiNK Therapeutics (NASDAQ:INKT) was provided by HC Wainwright & Co., and MiNK Therapeutics reiterated their buy rating.
When was the last upgrade for MiNK Therapeutics (INKT)?
There is no last upgrade for MiNK Therapeutics
When was the last downgrade for MiNK Therapeutics (INKT)?
There is no last downgrade for MiNK Therapeutics.
When is the next analyst rating going to be posted or updated for MiNK Therapeutics (INKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MiNK Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MiNK Therapeutics was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating MiNK Therapeutics (INKT) correct?
While ratings are subjective and will change, the latest MiNK Therapeutics (INKT) rating was a reiterated with a price target of $35.00 to $35.00. The current price MiNK Therapeutics (INKT) is trading at is $8.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.